Dogwood Therapeutics, Inc.
DWTX
$1.94
-$0.10-4.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.88% | 19.78% | -71.90% | -27.08% | 84.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.76% | 14.15% | -49.53% | 586.99% | 266.71% |
| Operating Income | -23.76% | -14.15% | 49.53% | -586.99% | -266.71% |
| Income Before Tax | -267.99% | 53.56% | 51.50% | -590.41% | -262.66% |
| Income Tax Expenses | -2,480,800.00% | -99.37% | 6,460.00% | -- | -- |
| Earnings from Continuing Operations | -202.82% | 54.36% | 51.08% | -590.34% | -262.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -202.82% | 54.36% | 51.08% | -590.34% | -262.68% |
| EBIT | -23.76% | -14.15% | 49.53% | -586.99% | -266.71% |
| EBITDA | -24.29% | -14.58% | 49.51% | -- | -- |
| EPS Basic | 83.04% | 98.24% | 95.86% | -299.33% | -73.82% |
| Normalized Basic EPS | 92.91% | 95.34% | 95.63% | -299.38% | -73.82% |
| EPS Diluted | 83.04% | 98.24% | 95.86% | -299.33% | -73.82% |
| Normalized Diluted EPS | 92.91% | 95.34% | 95.63% | -299.38% | -73.82% |
| Average Basic Shares Outstanding | 1,685.86% | 2,227.07% | 1,008.07% | 72.87% | 108.64% |
| Average Diluted Shares Outstanding | 1,685.86% | 2,227.07% | 1,008.07% | 72.87% | 108.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |